ライフサイエンスコーパス: calcimimetic

1 ct that can be prevented by treatment with a calcimimetic.

2 nificantly improves cortical BMD compared to calcimimetics.

3 osphonates, hormone replacement therapy, and calcimimetics.

4 in the ECD and 7TMD and the 7TMD site(s) for calcimimetics.

5 sphonates, and a new class of drugs known as calcimimetics.

6 ellular Ca2+ at the Ca2+ receptor are termed calcimimetics.

7 iven single orally administered doses of the calcimimetic agent AMG 073 ranging from 5 to 100 mg, or

8 aluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride.

9 as been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of d

10 posttransplant hyperparathyroidism with the calcimimetic agent cinacalcet.

11 Calcimimetic agents are a new class of drugs that increa

12 Calcimimetic agents directly inhibit PTH secretion by ac

13 oidism will indicate whether the efficacy of calcimimetic agents extends into the longer term.

14 discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyper

15 These calcimimetic agents hold promise as potential treatments

16 the administration of vitamin D analogs and calcimimetic agents may be augmented in the future by ag

17 Two calcimimetic allosteric modulators, NPS R-568 and Calind

18 We hypothesized that calcimimetics, allosteric modulators of the calcium-sens

19 In this study, the calcimimetic AMG 073 at doses up to 100 mg for 18 wk pro

20 approaches to the synthesis of new and known calcimimetic analogues employing enantiopure (1-naphthal

21 tentiated by allosteric activators including calcimimetics and l-amino acids.

22 CaSR agonists (calcimimetics) and antagonists (calcilytics) have been i

23 to sensing amino acids, GPRC6A is a cation-, calcimimetic-, and osteocalcin-sensing receptor and a ca

24 SR revealed conservation of both calcium and calcimimetic binding sites.

25 No patients received treatment with calcimimetics, bisphosphonates, vitamin D, or phosphate

26 Initial studies have shown that calcimimetics can acutely lower parathyroid hormone leve

27 Calcimimetics can effectively reduce PTH secretion in al

28 bjective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing ser

29 recently confirmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term reductio

30 The calcimimetic cinacalcet HCl acts on the calcium-sensing

31 e IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet.

32 ine, Hepes buffer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid se

33 The novel mode of action of the calcimimetic, combined with the glucose-dependence of th

34 In this study we showed that the calcimimetic compound NPS R-467, a selective calcium-sen

35 g concentrations of calcium, neomycin, and a calcimimetic compound suppress PTHrP secretion by mammar

36 Calcimimetic compounds could conceivably provide a speci

37 The discovery of calcimimetic compounds with potent and selective activit

38 he depolarization of the cell induced by the calcimimetic could be due to a direct action on the chan

39 An intravenously (IV) administered calcimimetic could improve adherence and reduce adverse

40 The calcimimetic drug R-568 reduces serum parathyroid hormon

41 We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secr

42 e the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cin

43 To evaluate the effect of the intravenous calcimimetic etelcalcetide on serum parathyroid hormone

44 dentified 17 patients that were treated with calcimimetics for pHPT.

45 osphonates and a new class of drugs known as calcimimetics have been used effectively in some patient

46 y has been shown to improve BMD in pHPT, but calcimimetics have recently been advocated as a medical

47 This study aims to determine the efficacy of calcimimetics in improving bone mineral density (BMD) in

48 milk protein concentration were mitigated by calcimimetic infusions.

49 An allosteric CaR agonist ("calcimimetic") is currently being tested for the treatme

50 um, strontium, aluminum, gadolinium, and the calcimimetic NPS 568 resulted in a dose-dependent stimul

51 luorescence imaging with fura-2, whether the calcimimetic NPS R-568 could activate Ca(2+)(i) oscillat

52 The calcimimetic NPS R-568 increases the potency of Ca2+ in

53 lation of the calcium-sensing receptor using calcimimetic or calcilytic agents may allow the anabolic

54 Calcimimetics promote CFTR opening by activating adenyla

55 treatment: (group 1) no treatment; (group 2) calcimimetic R-568 formulated in the diet; (group 3) R-5

56 cific CaR positive allosteric modulator, the calcimimetic R-568, mimics the suppressive effects of hi

57 stimulation of the CaSR, by Ca(2+) or by the calcimimetic R-568, produced a striking and time-depende

58 t of ring constrained analogues of the known calcimimetic R-568.

59 show that pharmacological CaSR activation by calcimimetics stimulates lung fluid secretion through CF

60 Calcimimetics such as NPS (R)-N-(3-phenylpropyl)-alpha-m

61 Calcimimetics target the calcium-sensing receptor and lo

62 receptor (Casr) by both hypercalcemia and a calcimimetic that decreases PTH secretion, demonstrating

63 such as NPS R-568 are allosteric modulators (calcimimetics) that activate CaR by increasing the appar

64 f calcium-free intestinal phosphate binders, calcimimetics to control parathyroid hormone secretion a

65 ity of Calindol, a novel chemically distinct calcimimetic, to activate a Ca(2+) receptor construct (T

66 s normalized in 35% of patients treated with calcimimetics versus 76% of surgical patients (P = 0.036

67 For hyperparathyroid states, calcimimetics, which increase activation of the CaR, hav

68 he treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) sy